Activity from announced rounds
Perceptive Advisors is the healthcare investment manager named in Superluminal’s financing and retained company records.
Superluminal develops small-molecule medicines using structural and experimental methods. Vaderis develops an oral treatment for hereditary hemorrhagic telangiectasia, while Imperative develops thromboembolic interventions. The manager remains separate from the Xontogeny venture arm.
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
Develops treatments for patients suffering from thromboembolic disease
Provides in-network psychiatric care using AI-powered technology